Pyrrolopyrimidine nucleosides and analogs thereof
The present disclosure provides pyrrolopyrimidine nucleoside analogs of the Formula I, Formula IA, Formula IB, or Formula II and phospholipid conjugates and pharmaceutical compositions thereof wherein R c and A are defined herein. Also presented are methods of treating and/or preventing viral infection and/or viral infection-associated disease or disorder with one or more compounds of Formula I, Formula IA, Formula IB, or Formula II.
1. A compound, wherein the compound is
Com-
pound
No.
Structure
7
8
10
11
12
14
16
17
18
19
20
21
22
27
28
29
30
31
32
33
34
35
36
37
38
39
41
42
43
44
45
47
48
49
50
51
54
61
63
65
66
68
69
72
73
78
81
82
83
84
85
86
88
91
93
94
95
96
98
100
103
104
106
108
110
114
115
116
117
120
121
122
123
124
125
128
129
130
131
132
134
136
138
140
142
144
9
13
15
23
24
25
26
40
52
53
55
56
57
58
59
60
62
64
67
70
74
75
79
80
87
89
90
92
97
99
101
102
105
109
112
113
118
119
135
127
or a pharmaceutically aceeptable salt, solvate, enantiomer,
diastereomer, racemate, or mixture thereof.
2. The compound of claim 1 , wherein the compound is compound no. 7
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
3. The compound of claim 1 , wherein the compound is compound no. 8
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
4. The compound of claim 1 , wherein the compound is compound no. 10
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
5. The compound of claim 1 , wherein the compound is compound no. 66
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
6. The compound of claim 1 , wherein the compound is compound no. 129
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
7. The compound of claim 1 , wherein the compound is compound no. 130
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
8. The compound of claim 1 , wherein the compound is compound no. 134
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
9. The compound of claim 1 , wherein the compound is compound no. 136
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
10. The compound of claim 1 , wherein the compound is compound no. 9
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
11. The compound of claim 1 , wherein the compound is compound no. 56
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
12. The compound of claim 1 , wherein the compound is compound no. 127
or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof.
13. A pharmaceutical composition comprising the compound of claim 1 , or a pharmaceutically acceptable salt, solvate, enantiomer, diastereomer, racemate, or mixture thereof, and a pharmaceutically acceptable carrier.